US Patent

US8492369 — Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same

Method of Use · Assigned to Clarus Therapeutics Inc · Expires 2030-12-20 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating testosterone deficiency or its symptoms using a pharmaceutical formulation of testosterone undecanoate.

USPTO Abstract

A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2506 — Aveed
U-2506 — Aveed
U-2506 — Aveed

Patent Metadata

Patent number
US8492369
Jurisdiction
US
Classification
Method of Use
Expires
2030-12-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Clarus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.